BPC-157 + TB-500 · 20 mg blend
The BPC-157/TB-500 blend has 10 mg and 20 mg total-size entries, distinct from the separate-vial stack. Listed specification: 20 mg.
Explore individual compounds, blends and separate-vial combinations. Compare specifications and follow each item to its reference guide.
The BPC-157/TB-500 blend has 10 mg and 20 mg total-size entries, distinct from the separate-vial stack. Listed specification: 20 mg.
This three-name blend is listed at 12 mg total. It is a separate catalog formulation from each of its standalone ingredients. Listed specification: 12 mg.
The BPC-157/TB-500 blend has 10 mg and 20 mg total-size entries, distinct from the separate-vial stack. Listed specification: 10 mg.
This listing combines cagrilintide and semaglutide under a 10 mg blend specification. Listed specification: 10 mg.
CJC-1295 and GHRP-2 are grouped in a 10 mg blend entry, separate from the CJC-1295/ipamorelin combinations. Listed specification: 10 mg.
This 10 mg blend explicitly names the no-DAC form of CJC-1295 together with ipamorelin. Listed specification: 10 mg.
GLOW is a named 70 mg blend reference. Its blend name is retained as a searchable catalog identity. Listed specification: 70 mg.
KLOW is listed as an 80 mg blend and has a separate identity from GLOW. Listed specification: 80 mg.
Neuroxelin is included in the blend collection with a 48 mg vial reference. Listed specification: 48 mg.
This 10 mg blend is indexed with a 5 mg tesamorelin plus 5 mg ipamorelin component label. Listed specification: 10 mg.
Tri-Heal is listed as a 45 mg blend; the reference identifier names TB-500, BPC-157 and KPV. Listed specification: 45 mg.